The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...
The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
BOCA RATON, Fla., July 24, 2025 /PRNewswire/ -- Ammunition Depot, a leading nationwide supplier of ammunition, firearms, and tactical gear, is proud to announce...
The Impact Portfolio Team is projected to expand Think Together's reach to over 100,000 more students across California by 2029.
SANTA ANA, Calif., July 24,...
Panel to explore regulatory challenges and alternatives to lithium-ion batteries in next-generation data centers
WAXAHACHIE, Texas, July 24, 2025 /PRNewswire/ -- Americase, a leading manufacturer of...
NEW YORK, July 24, 2025 /PRNewswire/ -- Tannenbaum Helpern is delighted to share that Victor Turcanu has joined Tannenbaum Helpern as an associate in...
AB “Ignitis grupė” (hereinafter – the Group) informs that on 23 July 2025 the Board of its subsidiary UAB “Ignitis renewables” (hereinafter – Ignitis Renewables) appointed the Chief Executive Officer (hereinafter – CEO) of Ignitis Renewables. The position will be assumed by Frank Oomen, a senior executive with a strong track record in renewables. The new Ignitis Renewables CEO is starting his five-year term from 1 September 2025.
AB “Ignitis grupė” (hereinafter – the Group) informs that on 23 July 2025 the Board of its subsidiary UAB “Ignitis renewables” (hereinafter – Ignitis Renewables) appointed the Chief Executive Officer (hereinafter – CEO) of Ignitis Renewables. The position will be assumed by Frank Oomen, a senior executive with a strong track record in renewables. The new Ignitis Renewables CEO is starting his five-year term from 1 September 2025.
SKINNSKATTEBERG, Sweden, July 24, 2025 /PRNewswire/ -- Shareholders in Systemair AB (publ), reg. no. 556160-4108 ("Systemair" or the "Company") are hereby invited to attend the Company's...
Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...
Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...
New market research series illustrates the impact of AI on telecoms
CAMPBELL, Calif., July 23, 2025 /PRNewswire/ -- Mobile Experts Inc. completed a series...